Beiley biofund (倍利生技創投), backed by Fubon Securities and tech leaders like Sunplus and Topco, is set to list on the Emerging Stock Market on Dec 9 with a reference price of NT$15.5. Chairman Hsien-hua Huang describes the firm as an "Active ETF" for biotech, offering investors professional oversight in a complex sector.

Portfolio & Financials:

• Capital & Performance: Capitalized at NT$2.05 billion, the firm reported an **EPS of NT$2.14** for the first ten months of 2024. Its Net Asset Value (NAV) stood at NT$12.8 in October.
• Asset Allocation: 70% of funds are allocated to "Growth-stage" companies (expected to reach milestones or IPO within 2–3 years), and 30% to "Seed-stage" startups.
• Key Holdings: The portfolio includes 18 companies (12 in drug dev, 2 in high-end medtech), with major stakes in Lin Bioscience (Belite Bio), Everest Medicines, and PanTherapeutics.
• Strategic Focus: Investments are concentrated in Precision Medicine, Regenerative Medicine, Longevity Economy, and AI Applications.

Resource: 又一家生技創投挑戰資本市場 倍利生技創投12月9日登錄興櫃